The serum LDH level and KELIM scores are potential predictors of a benefit from bevacizumab first-line therapy for patients with advanced ovarian cancer

The serum LDH level and KELIM scores are potential predictors of a benefit from bevacizumab first-line therapy for patients with advanced ovarian cancer

The survival benefit of first-line treatment with bevacizumab in advanced ovarian cancer patients are multifaceted. In our study, we aimed to identify potential markers of bevacizumab efficacy to help predict which patients would experience survival benefits. This was a retrospective analysis of 114...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical & translational oncology 2024-06
Hauptverfasser: Liu, Yi, Yuan, Lin, Lin, Zhang, Huixian, Miao, Huangyang, Meng, Cheng, Wenjun
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title Clinical & translational oncology
container_volume
creator Liu, Yi
Yuan, Lin
Lin, Zhang
Huixian, Miao
Huangyang, Meng
Cheng, Wenjun
description The survival benefit of first-line treatment with bevacizumab in advanced ovarian cancer patients are multifaceted. In our study, we aimed to identify potential markers of bevacizumab efficacy to help predict which patients would experience survival benefits. This was a retrospective analysis of 114 patients examined from January 1, 2015, to March 1, 2023, and data on clinical, biological, and imaging variables, such as ascites, serum LDH, and CA125, were extracted from electronic medical records. We performed a correlation analysis and principal component analysis to investigate correlations among variables and reduce their dimensionality. Then, univariate and multivariate Cox proportional hazards regression analyses were used to identify the predictors of progression-free survival. Favorable KELIM score (≥ 1, HR 0.376, 95% CI [0.202-0.700], p = 0.002), which indicated better chemosensitivity, and lower LDH levels (≤ 210 U/L, HR 38.73, 95% CI [6.108-245.6], p 
doi_str_mv 10.1007/s12094-024-03569-3
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3070841844</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3070841844</sourcerecordid><originalsourceid>FETCH-LOGICAL-c184t-e234bec626ea9a29e95fb4e1ba7bbc3eaf1d10437713e2999bdaae0c17a4ad653</originalsourceid><addsrcrecordid>eNpNkUFv1DAQhS0EoqXwBzigOXIJ2LGTrI-oFFqxiEs5W2NnrDVK4mA7i8ov4efisgVxGM170ps3h4-xl4K_EZwPb7NouVYNb-vIrteNfMTORa-r4F33-D99xp7l_I1X1QvxlJ3JneZKt_Kc_bo9EGRK2wz799cw0ZEmwGWET1f7m8-QXUyUARPBGgstJeAEa6IxuBJThugBwdJCPhTwKc7VHNGFn9uMFnxIuTRTWAjKgRKud-BjghVLqFUZfoRyAByPuDgaIR4xBVzA3dv0nD3xOGV68bAv2NcPV7eX183-y8eby3f7xomdKg21UllyfdsTamw16c5bRcLiYK2ThF6Mgis5DEJSq7W2IyJxJwZUOPadvGCvT71rit83ysXMITuaJlwobtlIPvCdqr9UjbanqEsx50TerCnMmO6M4OaeiDkRMZWI-UPEyHr06qF_szON_07-IpC_ARM4ico</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3070841844</pqid></control><display><type>article</type><title>The serum LDH level and KELIM scores are potential predictors of a benefit from bevacizumab first-line therapy for patients with advanced ovarian cancer</title><source>SpringerLink Journals - AutoHoldings</source><creator>Liu, Yi ; Yuan, Lin ; Lin, Zhang ; Huixian, Miao ; Huangyang, Meng ; Cheng, Wenjun</creator><creatorcontrib>Liu, Yi ; Yuan, Lin ; Lin, Zhang ; Huixian, Miao ; Huangyang, Meng ; Cheng, Wenjun</creatorcontrib><description>The survival benefit of first-line treatment with bevacizumab in advanced ovarian cancer patients are multifaceted. In our study, we aimed to identify potential markers of bevacizumab efficacy to help predict which patients would experience survival benefits. This was a retrospective analysis of 114 patients examined from January 1, 2015, to March 1, 2023, and data on clinical, biological, and imaging variables, such as ascites, serum LDH, and CA125, were extracted from electronic medical records. We performed a correlation analysis and principal component analysis to investigate correlations among variables and reduce their dimensionality. Then, univariate and multivariate Cox proportional hazards regression analyses were used to identify the predictors of progression-free survival. Favorable KELIM score (≥ 1, HR 0.376, 95% CI [0.202-0.700], p = 0.002), which indicated better chemosensitivity, and lower LDH levels (≤ 210 U/L, HR 38.73, 95% CI [6.108-245.6], p &lt; 0.001) were found to be independent predictors of a treatment benefit with bevacizumab in patients with advanced ovarian cancer. Regardless of LDH level, patients with favorable KELIM scores had a higher progression-free survival (PFS) benefit (p = 0.18). Among patients with unfavorable KELIM scores, those with higher LDH levels had the lowest PFS benefit (median: 11.5 months, p = 0.0059). Patients with poor chemosensitivity and low LDH levels are more likely to benefit from first-line bevacizumab treatment. The combination of the two markers can be a helpful predictor of patients who are most likely to benefit from treatment and a guide for treatment decisions-making. Retrospectively registered: 2020-MD-371, 2020.10.12.</description><identifier>ISSN: 1699-3055</identifier><identifier>EISSN: 1699-3055</identifier><identifier>DOI: 10.1007/s12094-024-03569-3</identifier><identifier>PMID: 38904923</identifier><language>eng</language><publisher>Italy</publisher><ispartof>Clinical &amp; translational oncology, 2024-06</ispartof><rights>2024. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c184t-e234bec626ea9a29e95fb4e1ba7bbc3eaf1d10437713e2999bdaae0c17a4ad653</cites><orcidid>0000-0002-5600-9982</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38904923$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liu, Yi</creatorcontrib><creatorcontrib>Yuan, Lin</creatorcontrib><creatorcontrib>Lin, Zhang</creatorcontrib><creatorcontrib>Huixian, Miao</creatorcontrib><creatorcontrib>Huangyang, Meng</creatorcontrib><creatorcontrib>Cheng, Wenjun</creatorcontrib><title>The serum LDH level and KELIM scores are potential predictors of a benefit from bevacizumab first-line therapy for patients with advanced ovarian cancer</title><title>Clinical &amp; translational oncology</title><addtitle>Clin Transl Oncol</addtitle><description>The survival benefit of first-line treatment with bevacizumab in advanced ovarian cancer patients are multifaceted. In our study, we aimed to identify potential markers of bevacizumab efficacy to help predict which patients would experience survival benefits. This was a retrospective analysis of 114 patients examined from January 1, 2015, to March 1, 2023, and data on clinical, biological, and imaging variables, such as ascites, serum LDH, and CA125, were extracted from electronic medical records. We performed a correlation analysis and principal component analysis to investigate correlations among variables and reduce their dimensionality. Then, univariate and multivariate Cox proportional hazards regression analyses were used to identify the predictors of progression-free survival. Favorable KELIM score (≥ 1, HR 0.376, 95% CI [0.202-0.700], p = 0.002), which indicated better chemosensitivity, and lower LDH levels (≤ 210 U/L, HR 38.73, 95% CI [6.108-245.6], p &lt; 0.001) were found to be independent predictors of a treatment benefit with bevacizumab in patients with advanced ovarian cancer. Regardless of LDH level, patients with favorable KELIM scores had a higher progression-free survival (PFS) benefit (p = 0.18). Among patients with unfavorable KELIM scores, those with higher LDH levels had the lowest PFS benefit (median: 11.5 months, p = 0.0059). Patients with poor chemosensitivity and low LDH levels are more likely to benefit from first-line bevacizumab treatment. The combination of the two markers can be a helpful predictor of patients who are most likely to benefit from treatment and a guide for treatment decisions-making. Retrospectively registered: 2020-MD-371, 2020.10.12.</description><issn>1699-3055</issn><issn>1699-3055</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpNkUFv1DAQhS0EoqXwBzigOXIJ2LGTrI-oFFqxiEs5W2NnrDVK4mA7i8ov4efisgVxGM170ps3h4-xl4K_EZwPb7NouVYNb-vIrteNfMTORa-r4F33-D99xp7l_I1X1QvxlJ3JneZKt_Kc_bo9EGRK2wz799cw0ZEmwGWET1f7m8-QXUyUARPBGgstJeAEa6IxuBJThugBwdJCPhTwKc7VHNGFn9uMFnxIuTRTWAjKgRKud-BjghVLqFUZfoRyAByPuDgaIR4xBVzA3dv0nD3xOGV68bAv2NcPV7eX183-y8eby3f7xomdKg21UllyfdsTamw16c5bRcLiYK2ThF6Mgis5DEJSq7W2IyJxJwZUOPadvGCvT71rit83ysXMITuaJlwobtlIPvCdqr9UjbanqEsx50TerCnMmO6M4OaeiDkRMZWI-UPEyHr06qF_szON_07-IpC_ARM4ico</recordid><startdate>20240621</startdate><enddate>20240621</enddate><creator>Liu, Yi</creator><creator>Yuan, Lin</creator><creator>Lin, Zhang</creator><creator>Huixian, Miao</creator><creator>Huangyang, Meng</creator><creator>Cheng, Wenjun</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5600-9982</orcidid></search><sort><creationdate>20240621</creationdate><title>The serum LDH level and KELIM scores are potential predictors of a benefit from bevacizumab first-line therapy for patients with advanced ovarian cancer</title><author>Liu, Yi ; Yuan, Lin ; Lin, Zhang ; Huixian, Miao ; Huangyang, Meng ; Cheng, Wenjun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c184t-e234bec626ea9a29e95fb4e1ba7bbc3eaf1d10437713e2999bdaae0c17a4ad653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, Yi</creatorcontrib><creatorcontrib>Yuan, Lin</creatorcontrib><creatorcontrib>Lin, Zhang</creatorcontrib><creatorcontrib>Huixian, Miao</creatorcontrib><creatorcontrib>Huangyang, Meng</creatorcontrib><creatorcontrib>Cheng, Wenjun</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical &amp; translational oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Yi</au><au>Yuan, Lin</au><au>Lin, Zhang</au><au>Huixian, Miao</au><au>Huangyang, Meng</au><au>Cheng, Wenjun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The serum LDH level and KELIM scores are potential predictors of a benefit from bevacizumab first-line therapy for patients with advanced ovarian cancer</atitle><jtitle>Clinical &amp; translational oncology</jtitle><addtitle>Clin Transl Oncol</addtitle><date>2024-06-21</date><risdate>2024</risdate><issn>1699-3055</issn><eissn>1699-3055</eissn><abstract>The survival benefit of first-line treatment with bevacizumab in advanced ovarian cancer patients are multifaceted. In our study, we aimed to identify potential markers of bevacizumab efficacy to help predict which patients would experience survival benefits. This was a retrospective analysis of 114 patients examined from January 1, 2015, to March 1, 2023, and data on clinical, biological, and imaging variables, such as ascites, serum LDH, and CA125, were extracted from electronic medical records. We performed a correlation analysis and principal component analysis to investigate correlations among variables and reduce their dimensionality. Then, univariate and multivariate Cox proportional hazards regression analyses were used to identify the predictors of progression-free survival. Favorable KELIM score (≥ 1, HR 0.376, 95% CI [0.202-0.700], p = 0.002), which indicated better chemosensitivity, and lower LDH levels (≤ 210 U/L, HR 38.73, 95% CI [6.108-245.6], p &lt; 0.001) were found to be independent predictors of a treatment benefit with bevacizumab in patients with advanced ovarian cancer. Regardless of LDH level, patients with favorable KELIM scores had a higher progression-free survival (PFS) benefit (p = 0.18). Among patients with unfavorable KELIM scores, those with higher LDH levels had the lowest PFS benefit (median: 11.5 months, p = 0.0059). Patients with poor chemosensitivity and low LDH levels are more likely to benefit from first-line bevacizumab treatment. The combination of the two markers can be a helpful predictor of patients who are most likely to benefit from treatment and a guide for treatment decisions-making. Retrospectively registered: 2020-MD-371, 2020.10.12.</abstract><cop>Italy</cop><pmid>38904923</pmid><doi>10.1007/s12094-024-03569-3</doi><orcidid>https://orcid.org/0000-0002-5600-9982</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1699-3055
ispartof Clinical & translational oncology, 2024-06
issn 1699-3055
1699-3055
language eng
recordid cdi_proquest_miscellaneous_3070841844
source SpringerLink Journals - AutoHoldings
title The serum LDH level and KELIM scores are potential predictors of a benefit from bevacizumab first-line therapy for patients with advanced ovarian cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T18%3A29%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20serum%20LDH%20level%20and%20KELIM%20scores%20are%20potential%20predictors%20of%20a%20benefit%20from%20bevacizumab%20first-line%20therapy%20for%20patients%20with%20advanced%20ovarian%20cancer&rft.jtitle=Clinical%20&%20translational%20oncology&rft.au=Liu,%20Yi&rft.date=2024-06-21&rft.issn=1699-3055&rft.eissn=1699-3055&rft_id=info:doi/10.1007/s12094-024-03569-3&rft_dat=%3Cproquest_cross%3E3070841844%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3070841844&rft_id=info:pmid/38904923&rfr_iscdi=true